Want to see SE:CLS.B full AI Analyst Report?
Top Page
Clinical Laserthermia Systems AB Class B
(CLS.B)
Select Model
Select Model
Rating:43Neutral
Price Target:
kr2.00
▲(6.38% Upside)
Action:Reiterated
Date:08/03/26
The score is held down primarily by very weak operating performance (declining revenue, negative margins, and substantial losses) and continued cash burn (negative operating and free cash flow). Technicals further weigh on the outlook as the stock trades well below major moving averages. A debt-free balance sheet provides some risk reduction but is not enough to offset weak fundamentals.
Positive Factors
Debt-free balance sheet
A debt-free capital structure materially reduces refinancing and interest risks, giving management flexibility to prioritize commercialization or R&D. Over months this improves solvency and lowers fixed financing costs, providing runway to execute a turnaround without near-term debt obligations.
Negative Factors
Declining revenue and negative margins
Sustained revenue decline and a shift to negative gross margins indicate persistent under-absorption of fixed costs, pricing or mix pressure, and weak demand. These dynamics make achieving sustainable profitability difficult without durable volume recovery or structural cost reductions.
Read all positive and negative factors
Positive Factors
Negative Factors
Debt-free balance sheet
A debt-free capital structure materially reduces refinancing and interest risks, giving management flexibility to prioritize commercialization or R&D. Over months this improves solvency and lowers fixed financing costs, providing runway to execute a turnaround without near-term debt obligations.
Read all positive factors
Clinical Laserthermia Systems AB Class B (CLS.B) vs. iShares MSCI Sweden ETF (EWD)
Market Cap
kr94.68M
Dividend YieldN/A
Average Volume (3M)62.02K
Price to Earnings (P/E)―
Beta (1Y)0.31
Revenue Growth-47.42%
EPS Growth44.01%
CountrySE
Employees13
SectorHealthcare
Sector Strength45
IndustryMedical - Specialties
Share Statistics
EPS (TTM)-1.35
Shares Outstanding47,479,410
10 Day Avg. Volume36,699
30 Day Avg. Volume62,021
Financial Highlights & Ratios
PEG Ratio0.07
Price to Book (P/B)2.55
Price to Sales (P/S)10.18
P/FCF Ratio-4.94
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)kr31.30M
Clinical Laserthermia Systems AB Class B Business Overview & Revenue Model
Company Description
Clinical Laserthermia Systems AB (publ) engages in the development of treatment tools for diseased tissue under the TRANBERG brand in Sweden. It offers TRANBERG, a thermal therapy system designed to deliver laser energy to heat the target tissue. ...
How the Company Makes Money
CLS generates revenue primarily by commercializing its laserthermia platform, which typically involves (1) sales of capital equipment (the laser/monitoring system installed at hospitals/clinics), (2) recurring sales of procedure-related consumable...
Clinical Laserthermia Systems AB Class B Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
62
Positive
Cash Flow
24
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 12.56M | 17.49M | 18.78M | 8.27M | 6.27M | 2.25M |
| Gross Profit | -4.10M | -29.00M | 10.42M | 3.00M | -2.79M | -3.63M |
| EBITDA | -37.95M | -26.41M | -44.76M | -68.41M | -57.84M | -57.05M |
| Net Income | -39.49M | -41.61M | -47.62M | -79.79M | -70.66M | -63.62M |
Balance Sheet | ||||||
| Total Assets | 66.57M | 76.49M | 78.56M | 57.73M | 49.51M | 66.74M |
| Cash, Cash Equivalents and Short-Term Investments | 3.87M | 21.55M | 22.51M | 15.33M | 10.59M | 31.17M |
| Total Debt | 0.00 | 0.00 | 224.00K | 454.00K | 30.68M | 273.50K |
| Total Liabilities | 22.07M | 10.00M | 12.88M | 14.20M | 41.64M | 45.55M |
| Stockholders Equity | 47.84M | 69.67M | 68.72M | 45.77M | 9.22M | 21.79M |
Cash Flow | ||||||
| Free Cash Flow | -32.35M | -36.00M | -58.92M | -71.95M | -71.25M | -66.73M |
| Operating Cash Flow | -25.04M | -33.20M | -56.45M | -66.45M | -70.69M | -66.17M |
| Investing Cash Flow | -7.31M | -2.80M | -7.47M | -5.50M | -886.00K | -408.00K |
| Financing Cash Flow | 20.02M | 35.04M | 71.10M | 76.69M | 61.84M | 85.88M |
Clinical Laserthermia Systems AB Class B Technical Analysis
Neutral
1.88
Price Trends
2.36
Negative
3.14
Negative
4.84
Negative
Market Momentum
-0.10
Negative
48.14
Neutral
70.69
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:CLS.B, the sentiment is Neutral. The current price of 1.88 is above the 20-day moving average (MA) of 1.87, below the 50-day MA of 2.36, and below the 200-day MA of 4.84, indicating a neutral trend. The MACD of -0.10 indicates Negative momentum. The RSI at 48.14 is Neutral, neither overbought nor oversold. The STOCH value of 70.69 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for SE:CLS.B.
Clinical Laserthermia Systems AB Class B Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
70 Outperform | kr1.19B | 23.96 | 14.08% | 0.28% | -0.27% | 93.40% | |
68 Neutral | kr5.87B | 28.28 | 22.81% | 2.28% | 1.42% | 10.40% | |
60 Neutral | kr1.36B | -274.06 | -1.22% | ― | 34.05% | -144.96% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | kr87.82M | -2.34 | -106.23% | ― | -97.37% | 25.28% | |
43 Neutral | kr94.68M | -1.41 | -66.41% | ― | -47.42% | 44.01% | |
38 Underperform | kr39.20M | -0.19 | -57.15% | ― | ― | 16.02% |
* Healthcare Sector Average
SE:CLS.B
Clinical Laserthermia Systems AB Class B
1.91
-7.58
-79.90%
SE:PAX
Paxman AB
59.80
-18.60
-23.72%
SE:RAY.B
RaySearch Laboratories AB
175.60
-60.41
-25.59%
SE:SPEC
SpectraCure AB
0.02
-0.10
-81.60%
SE:CRAD.B
C-Rad AB Class B
35.40
2.55
7.77%
SE:SPAGO
Spago Nanomedical AB
0.11
-0.07
-37.85%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.